It is therefore crucial to understand how naturalistic variation in BT over the sleep-wake interval affects CSF and plasma tau levels used for AD diagnosis, particularly in patients with thermoregulatory or sleep deficits. This evidence concerns the gene MAPT and Alzheimer disease.